SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Feb 6, 2020

Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Feb. 6, 2020 · CIK: 0001430306 · Accession: 0001387131-20-001062

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-235976

Date

Feb. 6, 2020

Author

TONIX

Form

CORRESP

Company

Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)

Letter

Tonix Pharmaceuticals Holding Corp.

Madison Avenue, Suite 1608

New York, New York 10022

February 6, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Tonix Pharmaceuticals Holding Corp.

Registration Statement on Form S-1 (File No. 333-235976)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 5:15 p.m., Eastern Standard Time, on February 6, 2020, or as soon as practicable thereafter.

Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]

U.S. Securities and Exchange Commission

February 6, 2020

Page 2

Very
truly yours,
TONIX
PHARMACEUTICALS HOLDINGS CORP.

Show Raw Text

CORRESP
1
filename1.htm

Tonix
Pharmaceuticals Holding Corp.

509
Madison Avenue, Suite 1608

New
York, New York 10022

February
6, 2020

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

 Re: Tonix
                                         Pharmaceuticals Holding Corp.

Registration
Statement on Form S-1 (File No. 333-235976)

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”)
hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared
effective by the Securities and Exchange Commission (the “Commission”) at 5:15 p.m., Eastern Standard Time,
on February 6, 2020, or as soon as practicable thereafter.

Please
call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with
any questions.

[Signature
page follows.]

U.S. Securities and Exchange Commission

February 6, 2020

Page 2

    Very
truly yours,

    TONIX
PHARMACEUTICALS HOLDINGS CORP.

    By:
    /s/ Bradley Saenger

    Name:
    Bradley Saenger

    Title:
    Chief Financial Officer

      -2-

SecProbe.io